Angiogenesis targeting in breast cancer
Fiche publication
Date publication
septembre 2007
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno, Pr FUMOLEAU Pierre, Dr FAVIER Laure
Tous les auteurs :
Fumoleau P, Coudert B, Mayer F, Isambert N, Favier L, Ferrant E
Lien Pubmed
Résumé
Several anti-angiogenic agents are under evaluation in breast cancer Currently, only bevacizumab has shown its efficacy, in combination with paclitaxel, on relapse-free survival in the metastatic setting. The combination of targeted therapies (for instance, trastuzumab plus bevacizumab, lapatinib plus pazopanib, etc.) is certainly of utmost interest, However, the anti-angiogenic agents not always bring in phase III the expected effects on patient survival, and an increased toxicity of combinations versus chemotherapy only has been observed. Outside the privileged neo-adjuvant setting, it appears difficult, for technical and ethical reasons, to obtain tissue samples before and after treatment to study predictive factors of drug response and to establish surrogate makers.
Référence
Bull Cancer. 2007;94(7 Suppl):F199-206.